Risk-adapted therapy for young children with medulloblastoma (SJYC07)

• Verfasst von: Robinson, Giles W. [VerfasserIn]
• Verfasst von: Korbel, Jan Oliver [VerfasserIn]
• Verfasst von: Jones, David T. W. [VerfasserIn]
• Verfasst von: Lichter, Peter [VerfasserIn]
• Verfasst von: Kool, Marcel [VerfasserIn]
• Verfasst von: Pfister, Stefan [VerfasserIn]
• Titel: Risk-adapted therapy for young children with medulloblastoma (SJYC07)
• Titelzusatz: therapeutic and molecular outcomes from a multicentre, phase 2 trial
• Verf.angabe: Giles W Robinson, Vasilisa A Rudneva, Ivo Buchhalter, Catherine A Billups, Sebastian M Waszak, Kyle S Smith, Daniel C Bowers, Anne Bendel, Paul G Fisher, Sonia Partap, John R Crawford, Tim Hassall, Daniel J Indelicato, Frederick Boop, Paul Klimo, Noah D Sabin, Zoltan Patay, Thomas E Merchant, Clinton F Stewart, Brent A Orr, Jan O Korbel, David T W Jones, Tanvi Sharma, Peter Lichter, Marcel Kool, Andrey Korshunov, Stefan M Pfister, Richard J Gilbertson, Robert P Sanders, Arzu Onar-Thomas, David W Ellison, Amar Gajjar, Paul A Northcott
• E-Jahr: 2018
• Jahr: May 16, 2018
• Umfang: 17 S.
• Fussnoten: Gesehen am 14.04.2020
• Titel Quelle: Enthalten in: The lancet <London> / Oncology
• Ort Quelle: London : The Lancet Publ. Group, 2000
• Jahr Quelle: 2018
• Band/Heft Quelle: 19(2018), 6, Seite 768-784
• ISSN Quelle: 1474-5488
• DOI: doi:10.1016/S1470-2045(18)30204-3
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1694458261

Abstract

Background - Young children with medulloblastoma have a poor overall survival compared with older children, due to use of radiation-sparing therapy in young children. Radiotherapy is omitted or reduced in these young patients to spare them from debilitating long-term side-effects. We aimed to estimate event-free survival and define the molecular characteristics associated with progression-free survival in young patients with medulloblastoma using a risk-stratified treatment strategy designed to defer, reduce, or delay radiation exposure. -